E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedReviewed
A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome.
Hickie, I B, Wilson, A J, Wright, J M et al. · The Journal of clinical psychiatry · 2000 · DOI
Quick Summary
This study tested whether a medication called moclobemide could help people with ME/CFS. Ninety patients received either moclobemide or a placebo for several weeks. About half of those taking moclobemide felt better, compared to one-third taking placebo—mainly reporting more energy and vigor rather than improvement in mood. The medication appeared to work best for people who also had immune system problems.
Why It Matters
This study addresses a critical unmet need by providing evidence that a pharmacological intervention can improve core ME/CFS symptoms—particularly energy and vigor—rather than only addressing comorbid depression. The finding that moclobemide's benefit is independent of mood changes suggests a direct effect on fatigue mechanisms rather than a secondary consequence of mood improvement, which could inform future mechanistic research and treatment approaches.
Observed Findings
- 51% of moclobemide-treated patients showed improvement versus 33% on placebo (odds ratio = 2.16).
- Subjective energy and vigor improvements were detectable within the first 2 weeks and increased over the study duration.
- Patients with concurrent immunologic dysfunction showed the greatest reduction in clinician-rated disability (mean difference = 0.8 standardized units).
- Moclobemide's benefit was not dependent on concurrent depressed mood, suggesting a mechanism independent of mood change.
Inferred Conclusions
- Moclobemide produces measurable improvement in key ME/CFS symptoms, particularly fatigue-related energy deficits.
- The mechanism of benefit appears to involve monoamine modulation affecting subjective vigor rather than mood correction.
- Patients with immunologic abnormalities may be a subgroup most likely to respond to MAO-I treatment.
- Moclobemide and related monoamine oxidase inhibitors warrant further investigation as potential ME/CFS therapies.
Remaining Questions
- What baseline characteristics or biomarkers predict which patients will respond to moclobemide?
- Does the benefit of moclobemide persist beyond the study period, and what is the optimal treatment duration?
What This Study Does Not Prove
This study does not establish that moclobemide is a cure or that it works for all ME/CFS patients. The confidence interval crosses 1.0 (0.9–5.1), meaning the difference between moclobemide and placebo, while suggestive, is not statistically definitive. It also does not explain why moclobemide works or identify which specific patients are most likely to benefit.
Tags
Symptom:Cognitive DysfunctionFatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:PEM Not DefinedSmall SampleWeak Case Definition
Metadata
- DOI
- 10.4088/jcp.v61n0909
- PMID
- 11030484
- Review status
- Editor reviewed
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.